CCTV+: Peng Liyuan sends best wishes to students with HIV on World AIDS Day
BEIJING, Dec. 2, 2021 /PRNewswire/ -- On the occasion of the 34th World AIDS Day Wednesday, Peng Liyuan, wife of Chinese President Xi Jinping, sent her best wishes to students in the Linfen Red Ribbon School in north China's Shanxi Province, the only facility set up in the country specifically for youngsters living with HIV/AIDS.   Peng,...
CGTN: Peng Liyuan sends message to Linfen Red Ribbon School students on World AIDS Day
BEIJING, Dec. 2, 2021 /PRNewswire/ -- Peng Liyuan, wife of Chinese President Xi Jinping and the World Health Organization (WHO)'s goodwill ambassador for tuberculosis and HIV/AIDS, sent a video message to the students of the Linfen Red Ribbon School in north China's Shanxi Province at an event marking the 34th World AIDS Day on Wednesday.   The...
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China
SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in mainland China (i.e., excluding Hong Kong, Macau and Taiwan regions) for the treatment of patients with advanced, metastatic or recurrent non-squamous non-small cell...
Christmas Comes Early For Children With Cancer Courtesy Of PM-International Malaysia
SUBANG-JAYA, Malaysia, Dec. 2, 2021 /PRNewswire/ -- Christmas cheer came early for the children at the National Cancer Society Malaysia (NCSM) as PM-International Malaysia donated RM500,000 to the Children's Home of Hope (CHH) at NCSM to help children in their fight against cancer. Children as young as one year old from around the country can have their treatment subsidized and...
SOPHiA GENETICS Announces Launch of DEEP-Lung-IV Multimodal Clinical Study
Study to leverage deep learning-enabled analysis of the aggregation of real-world multimodal data to validate predictive signatures associated with response to immunotherapy and prognosis of patients with stage IV non-small cell lung cancer Large-scale, multicentric real-world study aims to enroll 4,000 patients from approximately 30 sites across North America, Europe, and Latin...
Cue Health Receives Singapore HSA Authorization for its Molecular COVID-19 Test for Self-Testing
- The Cue COVID-19 Test was authorized for self-testing by the Singapore Health Sciences Authority (HSA) through its Pandemic Special Access Route (PSAR) - The HSA authorization of the Cue COVID-19 Test is for home use in both symptomatic and asymptomatic users, ages 2 years and up - Cue Health has...
Havas Health & You Appoints Tara Stewart As Managing Director, Havas Health CX
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- To help health companies navigate the immense shifts in patient and provider behavior around medical technologies and therapies brought about by COVID-19, Havas Health & You today announced that Tara Stewart, longtime pharmaceutical executive, will join HHCX on December 8th as its Managing Director. The...
Dr. Aletta Schnitzler Joins TurtleTree as Chief Scientific Officer
DAVIS, Calif. and SINGAPORE, Dec. 1, 2021 /PRNewswire/ -- Cell-based nutrition company TurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO). With her world-class expertise in cellular bioprocessing, Dr. Schnitzler's appointment marks a significant stride in TurtleTree's journey towards sustainable and efficient cellular food production. With her world-class expertise in cellular bioprocessing, Dr. Schnitzler’s appointment marks a significant...
Fifty percent recruitment milestone for PROPELLER prostate cancer trial
SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic 64Cu SAR-bisPSMA clinical trial (PROPELLER) in patients with untreated, confirmed prostate cancer, scheduled...
Licensing Partner of Shenzhen Chipscreen Biosciences – HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan. "Relapsed and/or refractory PTCL carries a grim prognosis with limited...
